Paper Details

  1. Home
  2. Paper Details

Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study.

Author: AtsumiTatsuya, FujiedaYuichiro, HisadaRyo, IshizakaSuguru, ItoYoichi M, KatoMasaru, KonoMichihito, NinagawaKeita, TsunetaSatonori, UjiieHideyuki

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 20 patients with SSc-ILD found that nintedanib, an inhibitor of tyrosine kinases, showed beneficial signals on cardiomyopathy associated with SSc. The rate of change in myocardial extracellular volume was significantly different between the nintedanib group and the control group.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Nintedanib is an inhibitor of tyrosine kinases that has been shown to slow the progression of interstitial lung disease (ILD), including ILD associated with SSc. The aim of this study was to explore the effect of nintedanib on cardiomyopathy associated with systemic sclerosis (SSc). MET...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/rheumatology/keac674

データ提供：米国国立医学図書館（NLM）

Nintedanib: A Potential Oasis for Systemic Sclerosis-Related Cardiomyopathy?

The journey through systemic sclerosis (SSc) can be a difficult one, filled with complications like interstitial lung disease (ILD) and cardiomyopathy. In this study, we explored the potential of nintedanib, a drug typically used for ILD, to also help with cardiomyopathy associated with SSc. The researchers, like skilled desert navigators, employed cardiac magnetic resonance (CMR) to assess the effects of nintedanib. They compared a group of patients taking nintedanib with a control group. The study revealed that nintedanib might offer a glimmer of hope for patients battling SSc-related cardiomyopathy.

A Glimmer of Hope in a Challenging Journey

The study showed that nintedanib had a beneficial effect on myocardial extracellular volume, a key factor in cardiomyopathy. This finding, like the discovery of a hidden water source in the desert, could lead to new treatments for SSc patients.

Navigating the Desert of Systemic Sclerosis

The study provides a beacon of hope for patients with SSc-related cardiomyopathy. It highlights the potential of nintedanib to improve their quality of life. Remember, even in the most challenging deserts, there are always oases waiting to be discovered.

Dr.Camel's Conclusion

The findings of this study suggest that nintedanib may offer hope for patients with SSc-related cardiomyopathy. It's an exciting discovery, but more research is needed to fully understand its potential benefits and how to best utilize it.

Date :
  1. Date Completed 2023-07-07
  2. Date Revised 2023-09-12
Further Info :

Pubmed ID

36458921

DOI: Digital Object Identifier

10.1093/rheumatology/keac674

Related Literature

Article Analysis
・Effects of nintedanib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.